Abstract: An embodiment of this disclosure provides a method and electronic device for attestation by proxy, the method comprising retrieving, by the electronic device, secure device data of the electronic device; performing, by an electronic device, attestation with an attestation server using a proxy server, wherein a validation result of the device is generated based on the secure device data; and communicating payment information with an application server when the validation result is trusted.

Abstract: The present invention relates to a method and system for providing content services to mobile devices. The method and system should provide these content services to the mobile devices while ensuring user privacy. The method and system should also allow one or more content providers that provide the content services to collect payment for the use of the content services. In one embodiment, a user makes a request for content from an affiliated content provider (Affiliated Content Provider A). This request travels from the wireless device (where it is a request over a radio frequency) thru one or more wireless infrastructure devices until it arrives as a Hypertext Transfer Protocol (HTTP) request over an Ethernet to a proxy server. The proxy server then requests the source Internet Protocol (IP) address of the wireless device that sent the request.

Abstract: Novel aromatic guanidine compounds having the formula: ##STR1## wherein: R.sub.1 is hydroxyl, methyl or hydroxymethyl and R.sub.2 is hydrogen or methyl, are found to have biological activity. The guanidine compounds and their salts are shown to be active as vasoconstrictor agents and create useful pharmaceutical preparations when deployed with a pharmaceutically acceptable carrier for administration to a host, e.g., man, requiring vasoconstrictive therapy.

Abstract: Novel aromatic guanidine compounds having the formula: ##STR1## wherein: R.sub.1 is hydroxyl, methyl or hydroxymethyl and R.sub.2 is hydrogen or methyl, are found to have biological activity. The guanidine compounds and their salts are shown to be activate as vasoconstrictor agents and create useful pharmaceutical preparations when deployed with a pharmaceutically acceptable carrier for administration to a host, e.g., man, requiring vasoconstrictive therapy.

Abstract: Novel aromatic guanidine compounds having the formula: ##STR1## wherein: R.sub.1 is hydroxyl, methyl or hydroxymethyl and R.sub.2 is hydrogen or methyl, are found to have biological activity. The guanidine compounds and their salts are shown to be active as vasoconstrictor agents and create useful pharmaceutical preparations when deployed with a pharmaceutically acceptable carrier for administration to a host, e.g., man, requiring vasoconstrictive therapy.

Abstract: A pharmaceutical preparation consisting of a pharmaceutical grade carrier and a therapeutically active amount of an aromatic guanidine compound having the formula: ##STR1## or a non-toxic acid addition salt thereof are found to have biologically useful activity. These guanidine preparations and salts are shown to be active as vasoconstrictor agents and obtain useful biological results when deployed with a pharmaceutically acceptable carrier for administration to a host, e.g., man, requiring vasoconstrictive therapy.

Abstract: Pharmaceutical preparations and methods of using the same to treat a host having a condition requiring vasoconstrictive therapy. The preparations comprise a pharmaceutically acceptable carrier and a guanidine compound, or non-toxic acid addition salt thereof, having the structural notation: ##SPC1##Wherein: R.sub.1 is hydrogen or alkyl having 1-4 carbon atoms; R.sub.2 is hydrogen, hydroxy, chloro, fluoro or bromo; and R.sub.3 is hydrogen or the same as R.sub.2 when R.sub.2 is chloro, bromo or fluoro.

Abstract: A novel aromatic guanidine compound having the formula: ##SPC1##Is found to have biological activity. This guanidine compound and its salts are shown to be active as vasoconstrictor agents and create useful pharmaceutical preparations when deployed with a pharmaceutically acceptable carrier for administration to a host, e.g., man, requiring vasoconstrictive therapy.